Neuphoria Therapeutics Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Burlington, MA
NEUP chart
What traders are saying about $NEUP
Latest postsNeuphoria Therapeutics Inc. news
- Neuphoria Therapeutics Inc. Estimates – NASDAQ:NEUP
TradingView ·
- Neuphoria (NEUP) Stock: Falls -0.83% — Where's the Floor? 2026-10-23 - Low Beta Factor
https://www.siam.in/ ·
- Neuphoria (NEUP) Stock: Falls -0.83% — Where's the Floor? 2026-10-23 - Quality ETF
www.dars.gov.et ·
- Neuphoria (NEUP) Stock: Falls -0.83% — Where's the Floor? 2026-10-23 - Double Top
https://www.dars.gov.et/ ·
- Neuphoria Therapeutics extends expiration of rights agreement to October 2027
Investing.com ·
- Form 8K Neuphoria Therapeutics Inc ADR For: 23 October By Investing.com
Investing.com Nigeria ·
- Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
proactiveinvestors.com ·
- Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
Yahoo Finance ·
- Scancell sees high demand in retail share offer, seals £15.7m from UK investors
proactiveinvestors.com ·
- SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612
proactiveinvestors.com ·
- Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell
Yahoo Finance ·
- Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Yahoo Finance ·
Neuphoria Therapeutics Inc. key financials
| USD | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | – | $15.6M | – | – |
| Net income | -$13.5M | -$369,632 | -$15.5M | -$21.4M |
| Diluted EPS | $-3.06 | $-0.23 | $-18.62 | $-0.02 |
| Total assets (year end) | – | $36.6M | $18.2M | – |
| Cash and equivalents (year end) | – | $22.2M | $4.3M | $10.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KCURRENT REPORT
- DEF 14ADEF 14A
- 10-K10-K
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-Q10-Q
- 10-Q10-Q
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-Q10-Q
- DEF 14ADEF 14A
About Neuphoria Therapeutics Inc.
- Ticker
- NEUP (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Burlington, MA
- Incorporated in
- Australia
- Fiscal year end
- June 30
- SEC CIK
- 1191070
- Former names
- BIONOMICS LIMITED/FI
Frequently asked questions
What exchange is Neuphoria Therapeutics Inc. listed on?
Neuphoria Therapeutics Inc. trades on the Nasdaq under the ticker symbol NEUP.
What industry is Neuphoria Therapeutics Inc. in?
Neuphoria Therapeutics Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Neuphoria Therapeutics Inc. headquartered?
Neuphoria Therapeutics Inc.'s business address on file with the SEC is in Burlington, MA.
When does Neuphoria Therapeutics Inc.'s fiscal year end?
Neuphoria Therapeutics Inc.'s fiscal year ends on June 30.
How much revenue did Neuphoria Therapeutics Inc. report?
Neuphoria Therapeutics Inc. reported $15.6M in revenue for calendar year 2025, according to its SEC filings.